CN1511523A - New use of bergenin in treating chronic prostatitis and proliferative diseases - Google Patents
New use of bergenin in treating chronic prostatitis and proliferative diseases Download PDFInfo
- Publication number
- CN1511523A CN1511523A CNA021591989A CN02159198A CN1511523A CN 1511523 A CN1511523 A CN 1511523A CN A021591989 A CNA021591989 A CN A021591989A CN 02159198 A CN02159198 A CN 02159198A CN 1511523 A CN1511523 A CN 1511523A
- Authority
- CN
- China
- Prior art keywords
- bergeninum
- bergenin
- treatment
- prostate
- proliferative diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to the new use of bergenin in treating chronic prostatitis and proliferative diseases. Bergenin has obvious effects of resisting prostate hyperplasia, improving patient's clinical symptoms, reducing volume of prostate and promoting diuresis. In addition, bergenin can inhibit hyperplasia of fibrous tissue, reduce inflammation reaction and increase local blood flow in treating other proliferative diseases.
Description
Invention field
The invention relates to the new purposes in Bergeninum treatment chronic prostatitis and the anti-proliferative disease, belong to the field of Chinese medicines.
Background technology
Bergeninum (bergeninum) records in " one one the 169th page of Chinese pharmacopoeia 2000, Bergeninum has another name called Bergenin, bergenin, bergenin, bergenit, the Bergeninum pharmacopeia is called bergeninum, a lot of bibliographical informations are called bergenin, the effect of Bergeninum tool relieving cough and expelling phlegm is used for chronic bronchitis.Existing report is used for anticancer, and the anti HIV-1 virus effect is arranged.Its structural formula is as follows:
Bergeninum
Bergeninum
The medical material that contains the Rhizoma Seu Herba Bergeniae element has twenties kind of plant:
1, saxifragaceae plant:
Rhizoma Seu Herba Bergeniae is saxifragaceae plant Rhizoma Seu Herba Bergeniae Bergenia purpurascens
(Hook.f.etThoms.) herb of Engl. (do medicinal, is called rock by its rhizome
Rhizoma Acori Graminei)
Rhizoma Seu Herba Bergeniae is saxifragaceae plant Rhizoma Seu Herba Bergeniae Bergenia crassifolia
(L.) herb of Fritsch.
Rhizoma Bergeniae scopulosae is saxifragaceae plant Qinling Mountains Rhizoma Seu Herba Bergeniae rhizome Bergenia scopulosa
T.P.Wang.
The Yunnan Rhizoma Seu Herba Bergeniae is saxifragaceae plant Yunnan Rhizoma Seu Herba Bergeniae Bergenia purpurascens
(Hook.f.etThoms.)Engl.var.delavayi(Franch.)et.I
Rm. herb
Herba Saxifragae is saxifragaceae plant Saxifraga Stolonifera Meerb.
Herba astilbes chinensis is the herb (its rhizome is done medicinal, is called Herba Eupatorii Heterophylli) of saxifragaceae plant Herba astilbes chinensis Astilbe chinensis (Maxim.) Franch.etSav. and big Herba astilbes chinensis Astilbe grandis Stapf ex Wils.
2, Myrsinacea plant
Herba Ardisiae Japonicae (having another name called PINGDIMU, Herba Ardisiae Japonicae) Ardisia japonica (Thunb.) Bl.
Radix Ardisiae Crenatae Ardisia crenata Sims.
Radix Ardisiae Crispae crispa (Thunb.) A.DC
Acid Herba corydalis edulis Ardisia solanacea Roxb..
Summary of the invention
The objective of the invention is to the new purposes in open Bergeninum treatment chronic prostatitis and the anti-proliferative disease.
The effect of Bergeninum in treatment chronic prostatitis and anti-proliferative disease is to be confirmed by following effect experiment, clinical experiment.
Experimental example 1Bergeninum is to the influence of experimental rat prostatic hyperplasia
1. weight of prostate:
Use the Wistar rat, modeling testosterone propionate 5mg/kg, olive oil dilution (5mg/ml), subcutaneous injection, continuous 28 days, after testosterone propionate stops injection, be subjected to reagent 21 days continuously, model group subcutaneous injection water for injection 0.3ml/ only, (Bergeninum concentration is 1.6% to medicine group subcutaneous injection, small dose group 0.15ml/, heavy dose of group 0.3ml/ is only), the 22nd day all rats take off cervical vertebra and put to death, prostate is got in dissection, observe prostate swelling situation, congested situation, and prostate is weighed, result of the test sees the following form;
Medicine rings the prostate ghost image
Group weight of prostate (mg)
Model group: 404 ± 70
Bergeninum small dose group 345 ± 51
The heavy dose of group 321 ± 37 of Bergeninum
※
Compare ※ p＜0.05 with the normal saline group.
Compare with model group: Bergeninum is compared with model group and can obviously be reduced prostate heavily, and its heavy dose of congested situation obviously reduces, other in confused situation showing.
2. pathological change
Model group: the prostate body of gland enlarges obviously, and body of gland quantity increases, and phenomenon is back-to-back arranged, and the cell number of plies reaches the 3-5 layer, and body of gland becomes papillary hyperplasia, and nipple is more, and a matter proliferation of smooth muscle is obvious.
The Bergeninum small dose group: prostate body of gland moderate enlarges, and body of gland quantity reduces, and phenomenon is back-to-back arranged, and cell number of plies 1-3 layer has papillary hyperplasia, and a matter proliferation of smooth muscle is not obvious.
The heavy dose of group of Bergeninum: the prostate body of gland slightly enlarges, and body of gland quantity is than the apparent in view minimizing of model group, little phenomenon back-to-back, and cell number of plies 1-3 layer, papillary hyperplasia reduces, and a matter proliferation of smooth muscle is not obvious.
3. conclusion: the medication group has tangible anti-prostatic hyperplasia effect than model group.
Experimental example 2Bergeninum preparation (the flat capsule in prostatitis) is to the effect of treatment prostatic hyperplasia
Use the Bergeninum preparation and treat prostatic hyperplasia 56 examples altogether, its clinical observation research data is as follows:
One, case source: be the outpatient.
Two, age distribution: 51～76 years old, average 64.8 years old
Three, the course of disease: June～11 year, average 4.3 years.
Four, diagnostic criteria
(1) cardinal symptom and medical history: frequent micturition, urgent micturition, nocturia increases, and dysuria is carrying out property and increases the weight of, acraturesis, the urine journey shortens, and urine retention or dripping has acute urinary retention or urine retention history person repeatedly.
(2) have above symptom, and in conjunction with anus examine, ultrasound diagnosis prostate size and residual urine are measured has one to support primary disease diagnosis person to make a definite diagnosis in three detections.
One, Therapeutic Method
Capsular preparation is put down in the prostatitis: accurately take by weighing Bergeninum 150g, add equivalent starch mix homogeneously, make 1000 of capsules altogether.Every contains the plain 0.15g of Rhizoma Seu Herba Bergeniae
The flat capsule in oral prostatitis, every day 2 times, each 2, and advise patient's polydipsia water.Taking for 8 weeks continuously is a course of treatment, carries out efficacy evaluation after treating a course of treatment.
Two, efficacy assessment standard
(1) clinical recovery: the urine circulation is smooth, clinical symptoms, cardinal symptom complete obiteration, and the ultrasound diagnosis residual urine is zero;
(2) produce effects: unobstructed micturition, nocturia are below 2 times, and the ultrasound diagnosis residual urine is below 30ml, and anus touch or ultrasound diagnosis prostate dwindle 1 level time person;
(3) effective: acute urinary retention is alleviated, and nocturia is below 5 times, and the ultrasound diagnosis residual urine is reduced to the following person of 50ml;
(4) invalid: clinical symptoms does not have improvement, and ultrasound diagnosis does not have the changer.
Three, efficacy analysis
After a course of therapy, 19 examples of fully recovering for 56 routine near-mid terms, produce effects 26 examples, effective 7 examples, invalid 4 examples, total effective rate 92.86%.All cases have all been carried out ultrasound diagnosis before and after treatment during this time, to determine prostate size (cm
3), the situation of change of residual urine volume (ml).The result shows, prostate volume dwindle with the minimizing of residual urine volume and treatment before contrast notable difference (P＜0.01) is arranged.Concrete outcome sees the following form:
Treat back T value P value before detecting the title treatment
Prostate size 11.894 8.332 2.498 P＜0.01
(cm
3)
Residual urine volume (ml) 63.155 39.605 3.171 P＜0.01
Four, conclusion
By above clinical research data analysis as seen, the flat capsule in prostatitis, be that Bergeninum has significant curative effect aspect the treatment prostatic hyperplasia, not only can obviously improve patient's clinical symptoms, and has a prostate volume of dwindling, the effect that promotion is urinated points out its therapeutical effect and this medicine to suppress proliferation of fibrous tissue, the reaction that reduces inflammation, and effects such as increase regional blood flow are relevant.
Experimental example 3Bergeninum preparation (RUKUAIXIAO capsule) is to the effect of treatment cyclomastopathy
We use Bergeninum preparation (RUKUAIXIAO capsule) and treat cyclomastopathy 60 examples altogether, now its clinical observation research data are summarized as follows:
One, example source: be the outpatient.
Two, distribute age: 20～42 years old, average 36.1 years old.
Three, the course of disease: January～10 year, average 13 months.
Four, diagnostic criteria
A) mammary gland is one-sided or bilateral can be laid one's hand on and flat or irregular swollen thing, and there is granular sensation on the surface, touches a tender spot, tough, the indefinite border of matter, does not have adhesion with skin and deep; And most with symptoms such as mastalgias, continuous 3 months can not spontaneous remission person.
B) turn out to be cyclomastopathy through B ultrasonic, mammary gland noctovisor scan or other imaging examination.
C) get rid of other mastopathy such as physiological mastalgia, breast carcinoma, mammary gland fibroma.
Five, Therapeutic Method
The capsular preparation of RUKUAIXIAO: accurately take by weighing Bergeninum 150g, add equivalent starch mix homogeneously, make 1000 of capsules altogether.Every contains the plain 0.15g of Rhizoma Seu Herba Bergeniae
The RUKUAIXIAO capsule oral, every day 3 times, each 2.Taking 1 month continuously is a course of treatment, carries out efficacy evaluation after treating two courses of treatment.(patient agrees after consulting, and begins certainly to take medicine not accept other any type of treatment in back 5 months, to guarantee the reliability of efficacy evaluation.)
Six, efficacy assessment standard
D) clinical recovery: lump disappears, mastalgia disappears, and drug withdrawal was not recurred after 3 months;
E) produce effects: lump dwindles, and dwindles more than 1/2 before the treatment, and mastalgia disappears;
F) effective: lump dwindles, and dwindles below 1/2 before the treatment, and mastalgia alleviates;
G) invalid: the lump no change, pain does not have alleviation.
Seven, efficacy analysis
60 routine patients take medicine continuously after two courses of treatment and to follow up a case by regular visits in 3 months, and the result shows: clinical recovery 26 examples (43.3%), and produce effects 18 examples (30%), effective 10 examples (16.7%), invalid 6 examples (10%), total effective rate is 90%.Carried out in 3 months afterwards following up a case by regular visits to the second time, wherein have 47 examples not carry out any other treatment during this period, comprise clinical recovery person's 21 examples, produce effects person's 16 examples, responder's 8 examples, nonresponder's 2 routine concrete conditions variations see the following form:
Stable/recovery from illness long-term effective rate that N increases the weight of/recur to take a turn for the better
Fully recover 25 00 25 100%
Produce effects 16 0 12 4 87.50%
Effective 4130 87.50%
Invalid 21100
Amount to 47 2 16 29 95.74%
Eight, conclusion
The criterion of therapeutical effect of being taked when using RUKUAIXIAO capsule for treating primary disease be at present general standard, but in order to confirm the definite curative effect of this medicine, satisfying increases for the second time following up a case by regular visits to of (treatment finishing back 6 months), found that: RUKUAIXIAO after capsular 6 months curative effect be better than curative effect after 3 months, illustrate that Rhizoma Seu Herba Bergeniae have the effect of definite treatment cyclomastopathy.
Embodiment 1
Accurately take by weighing Bergeninum 150g, add equivalent starch mix homogeneously, make 1000 of capsules altogether.Every contains the plain 0.15g of Rhizoma Seu Herba Bergeniae,, every day 2 times, each 2, and advise patient's polydipsia water.
Embodiment 2
Accurately take by weighing Bergeninum 150g, add equivalent starch mix homogeneously, use an amount of alcohol granulation, through the pelletizing machine granulate, tabletting is made 1000 altogether.Every contains the plain 0.15g of Rhizoma Seu Herba Bergeniae, every day 3 times, each 2.
Claims (3)
1, the application of Bergeninum in treatment proliferative disease medicine.
2, the application of Bergeninum as claimed in claim 1 in treatment proliferative disease medicine specifically is meant the application in treatment prostatic hyperplasia, cyclomastopathy medicine.
3, the application of Bergeninum in treatment chronic prostatitis medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02159198 CN1213750C (en) | 2002-12-30 | 2002-12-30 | New use of bergenin in treating chronic prostatitis and proliferative diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02159198 CN1213750C (en) | 2002-12-30 | 2002-12-30 | New use of bergenin in treating chronic prostatitis and proliferative diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1511523A true CN1511523A (en) | 2004-07-14 |
| CN1213750C CN1213750C (en) | 2005-08-10 |
Family
ID=34237358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 02159198 Expired - Fee Related CN1213750C (en) | 2002-12-30 | 2002-12-30 | New use of bergenin in treating chronic prostatitis and proliferative diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1213750C (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101899052A (en) * | 2009-05-31 | 2010-12-01 | 中国医学科学院药物研究所 | B-crystal form solid matter of bergenin and preparation method and application thereof |
| CN101972287A (en) * | 2010-10-18 | 2011-02-16 | 山东大学威海分校 | Preparation method of Chinese astilbe extract and purpose thereof |
| CN101444566B (en) * | 2008-12-19 | 2011-04-20 | 居龙涛 | Application of saxifrage for preparing medicaments for treating benign tumor of thyroid |
| CN103385943A (en) * | 2013-07-29 | 2013-11-13 | 奉节县瑞康中药材种植有限公司 | Traditional Chinese medicine for treating cancer and preparation method thereof |
| CN103656530A (en) * | 2013-12-23 | 2014-03-26 | 刘永秋 | Traditional Chinese medicine composition for treating breast hyperplasia |
| CN106632373A (en) * | 2016-09-30 | 2017-05-10 | 陕西科技大学 | A D crystal form solid substance of bergenin, a preparing method thereof and uses of the substance |
| CN109718233A (en) * | 2019-02-28 | 2019-05-07 | 天津国际生物医药联合研究院 | Bergenin is in preparation for treating the application in pulmonary fibrosis disease drug |
-
2002
- 2002-12-30 CN CN 02159198 patent/CN1213750C/en not_active Expired - Fee Related
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101444566B (en) * | 2008-12-19 | 2011-04-20 | 居龙涛 | Application of saxifrage for preparing medicaments for treating benign tumor of thyroid |
| CN101899052A (en) * | 2009-05-31 | 2010-12-01 | 中国医学科学院药物研究所 | B-crystal form solid matter of bergenin and preparation method and application thereof |
| CN101899053A (en) * | 2009-05-31 | 2010-12-01 | 中国医学科学院药物研究所 | C crystal form solid matter of bergenin and preparation method and application thereof |
| CN101899052B (en) * | 2009-05-31 | 2014-08-27 | 中国医学科学院药物研究所 | B-crystal form solid matter of bergenin and preparation method and application thereof |
| CN101899053B (en) * | 2009-05-31 | 2014-09-24 | 中国医学科学院药物研究所 | C crystal form solid matter of bergenin and preparation method and application thereof |
| CN101972287A (en) * | 2010-10-18 | 2011-02-16 | 山东大学威海分校 | Preparation method of Chinese astilbe extract and purpose thereof |
| CN103385943A (en) * | 2013-07-29 | 2013-11-13 | 奉节县瑞康中药材种植有限公司 | Traditional Chinese medicine for treating cancer and preparation method thereof |
| CN103385943B (en) * | 2013-07-29 | 2015-11-18 | 奉节县瑞康中药材种植有限公司 | Chinese medicine of a kind of Therapeutic cancer and preparation method thereof |
| CN103656530A (en) * | 2013-12-23 | 2014-03-26 | 刘永秋 | Traditional Chinese medicine composition for treating breast hyperplasia |
| CN103656530B (en) * | 2013-12-23 | 2015-08-19 | 刘永秋 | A kind of Chinese medicine composition for the treatment of cyclomastopathy |
| CN106632373A (en) * | 2016-09-30 | 2017-05-10 | 陕西科技大学 | A D crystal form solid substance of bergenin, a preparing method thereof and uses of the substance |
| CN109718233A (en) * | 2019-02-28 | 2019-05-07 | 天津国际生物医药联合研究院 | Bergenin is in preparation for treating the application in pulmonary fibrosis disease drug |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1213750C (en) | 2005-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1803177A (en) | Chinese medicinal composition for treating gout and its preparing process | |
| CN1683001A (en) | Chinese medicine for treating gout | |
| CN1289137C (en) | Medicine for treating mammary gland proliferation, its preparation method and application | |
| CN1213750C (en) | New use of bergenin in treating chronic prostatitis and proliferative diseases | |
| CN1092981C (en) | Medicine for curing arthralgia-syndrome resulted from wind,cold and dampness and its preparation method | |
| CN1836724A (en) | Medicine for treating climacteric metancholia | |
| CN1314397C (en) | Effective site extract of lotus plumule and its usage | |
| CN1086289C (en) | Medicine for treating diabetes and nephrosis containing rheinic acid | |
| CN1824204A (en) | Medicinal composition for treating acute urarthritis and its preparation method | |
| CN1850248A (en) | Chinese medicine capsule for treating hyperplasia mammary glands and preparing method | |
| CN1875976A (en) | Use of tanshinone compound in preparation of medicine for treating prostate hyperplasia | |
| CN1824075A (en) | Medicinal composition for treating hemicrania and its application | |
| CN1152704C (en) | Anticancer oral liquid and its preparing process | |
| CN1265905A (en) | Rhodiola rosea injection for treating angina pectoris of coronary heart disease | |
| CN1872165A (en) | A medicine combination, preparation method and method for controlling quality | |
| CN1785410A (en) | Preparation method of ready prepared chinese medicinal granules for treathing pains | |
| CN101879227B (en) | Chinese medicinal composition for treating protrusion of lumbar intervertebral disci and preparation method thereof | |
| CN1248716C (en) | Medicine for treating urinary stone and its preparation method | |
| CN1824253A (en) | Medicine for treating fatty liver and its preparation method | |
| CN1724071A (en) | Novel use of cell wall skeleton of red nocar-ray-fungus for treating liver diseases | |
| CN1213749C (en) | Prepn. of obakulactone contd. medicine for treating hemorrhoid, and its use | |
| CN1899436A (en) | Method for preparing Chinese medicine compound preparation and use | |
| CN1872317A (en) | Application of medication of containing red sage root in resistant medication anti aspirin | |
| CN1660329A (en) | Medication of possessing effect for reducing fat and treating fatty liver | |
| CN1613461A (en) | Arthralgia removing pills and their preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Beijing Kairui Chuangxin Pharmaceutical Sci. & Tech. Co., Ltd. Assignor: Zhang Hong Contract fulfillment period: 2008.11.25 to 2022.11.24 contract change Contract record no.: 2009990000518 Denomination of invention: New use of bergenin in treating chronic prostatitis and proliferative diseases Granted publication date: 20050810 License type: Exclusive license Record date: 2009.5.18 |
|
| LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2008.11.25 TO 2022.11.24; CHANGE OF CONTRACT Name of requester: BEIJING KAIRUI INNOVATION PHARMACEUTICAL TECHNOLOG Effective date: 20090518 |
|
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050810 Termination date: 20131230 |